Literature DB >> 8420409

Bronchoalveolar lavage. Quantitation of intraalveolar fluid?

P Von Wichert1, K Joseph, B Müller, W M Franck.   

Abstract

A precise calculation of the amount of intraalveolar fluid is the basis of a quantitative analysis of intraalveolar compounds. Different approaches have been made to cover this important problem. Here, we report a comparative study with five markers: 99mTc-DTPA, 51Cr-EDTA, inulin, urea, and methylene blue in animal experiments as well as in human experiments. The marker substances were added to the lavage fluid, and the "dilution" of the markers, i.e., the alveolar fluid, was calculated. The results showed that in animals with healthy lungs the tracer methods are able to calculate amounts of intraalveolar fluid that are comparable to morphologic findings. In animals as well as in humans, methylene blue and inulin were shown to be useless in determining alveolar fluid volume compared with the tracer methods. In humans, the calculations with the urea method and with Tc-DTPA were in the same magnitude, but there was no individual correlation. We conclude that, at present, the methods to quantitate alveolar fluid volume lack precision and add nothing to a deeper understanding of alveolar biology.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8420409     DOI: 10.1164/ajrccm/147.1.148

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  8 in total

1.  Biochemical parameters of bronchoalveolar lavage fluid in fat embolism.

Authors:  Georgia Karagiorga; George Nakos; Eftychia Galiatsou; Marilena E Lekka
Journal:  Intensive Care Med       Date:  2005-12-02       Impact factor: 17.440

2.  Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice.

Authors:  Johanna Berkhout; Maria J Melchers; Anita C van Mil; Seyedmojtaba Seyedmousavi; Claudia M Lagarde; Wright W Nichols; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

3.  Intrapulmonary posaconazole penetration at the infection site in an immunosuppressed murine model of invasive pulmonary aspergillosis receiving oral prophylactic regimens.

Authors:  Seyedmojtaba Seyedmousavi; Roger J M Brüggemann; Willem J G Melchers; Paul E Verweij; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

4.  Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model.

Authors:  Seyedmojtaba Seyedmousavi; Roger J M Brüggemann; Jacques F Meis; Willem J G Melchers; Paul E Verweij; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

5.  Intrapulmonary protein leakage in immunocompromised children and adults with pneumonia.

Authors:  F Ratjen; W Havers; J Braun
Journal:  Thorax       Date:  1999-05       Impact factor: 9.139

6.  Posaconazole prophylaxis in experimental azole-resistant invasive pulmonary aspergillosis.

Authors:  Seyedmojtaba Seyedmousavi; Johan W Mouton; Willem J G Melchers; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

7.  Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin.

Authors:  John E Conte; Jeffrey A Golden; Juliana E Kipps; Emil T Lin; Elisabeth Zurlinden
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Alveolar macrophage activation and an emphysema-like phenotype in adiponectin-deficient mice.

Authors:  R Summer; F F Little; N Ouchi; Y Takemura; T Aprahamian; D Dwyer; K Fitzsimmons; B Suki; H Parameswaran; A Fine; K Walsh
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-03-07       Impact factor: 5.464

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.